Vaccine News and Research

Latest Vaccine News and Research

The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children aged 6-11

The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in children aged 6-11

Multicenter study determines the efficacy of SARS-CoV-2 vaccination against Post-Acute Sequelae of COVID-19

Multicenter study determines the efficacy of SARS-CoV-2 vaccination against Post-Acute Sequelae of COVID-19

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

IVI and partners to provide two doses of oral vaccine to 100,000 people at risk of cholera in Ethiopia

IVI and partners to provide two doses of oral vaccine to 100,000 people at risk of cholera in Ethiopia

Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines

Investigating effectiveness of mRNA booster against SARS-CoV-2 Omicron in individuals primed with mRNA or inactivated virus vaccines

Exploring short-term effectiveness of COVID-19 booster vaccine and stable CD8+ T cell memory after three doses

Exploring short-term effectiveness of COVID-19 booster vaccine and stable CD8+ T cell memory after three doses

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

SARS-CoV-2 N-terminal domain modulates S1/S2 cleavage and spike-mediated functions

New project aims to improve exercise adherence in hemodialysis patients

New project aims to improve exercise adherence in hemodialysis patients

An Ad5 vectored COVID vaccine expressing an S1-N fusion protein

An Ad5 vectored COVID vaccine expressing an S1-N fusion protein

T-cell responses after COVID-19 and vaccinations

T-cell responses after COVID-19 and vaccinations

Study shows how MS patients treated with Rituximab react to COVID-19 vaccination

Study shows how MS patients treated with Rituximab react to COVID-19 vaccination

Phase 1 clinical trial of vaccine for rare but deadly mosquito-borne viruses shows promising results

Phase 1 clinical trial of vaccine for rare but deadly mosquito-borne viruses shows promising results

KHN’s ‘What the Health?’: The invisible pandemic

KHN’s ‘What the Health?’: The invisible pandemic

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

Phase 1 trial of COVID-19 PTXCOVID19-B vaccine

Clonality and magnitude of SARS-CoV-2-reactive CD4+ T cells in COVID-19 convalescent patients after vaccination

Clonality and magnitude of SARS-CoV-2-reactive CD4+ T cells in COVID-19 convalescent patients after vaccination

Study finds recent influenza vaccination is associated with an appreciable reduction in the risk of SARS-CoV-2 infection and COVID-19 severity

Study finds recent influenza vaccination is associated with an appreciable reduction in the risk of SARS-CoV-2 infection and COVID-19 severity

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

COVID-19 booster vaccination strategy found to be highly cost-effective in Australia

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

Study projects the COVID-19 burden caused by Omicron infections in mainland China should the zero-COVID policy be lifted

SK bioscience's typhoid vaccine licensed for export by Korean Ministry of Food and Drug Safety

SK bioscience's typhoid vaccine licensed for export by Korean Ministry of Food and Drug Safety

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

Imprinted antibody responses towards SARS-CoV-2 Omicron subvariants

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.